Skip to content
lifestyle.washingtonguardian.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Vector Sciences & Therapeutics
Vector Science and Therapeutics Corp. Announces Collaboration with SAFE Investment in Gary Payton’s Scoreboard
October 7, 2026
Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options
August 25, 2026
Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online
August 24, 2026
Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides
August 20, 2026
/C O R R E C T I O N — Vector Sciences & Therapeutics/
August 19, 2026
Verlytix Launches as a Related Company to LyoGenesis Manufacturing
August 18, 2026
Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings
August 17, 2026
Vector Science & Therapeutics Corp., LyoGenesis Plus and Wynn Pharmaceuticals Announce Strategic Collaboration to Develop and Manufacture Critical Care Medical Products
July 28, 2026
Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
July 24, 2026
Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels
July 21, 2026
1
2
3
Next Page
→